IMS 2022 | Real-world safety & efficacy of isatuximab-pomalidomide-dexamethasone in R/R multiple myeloma
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the findings of a real-world study evaluating the real-world safety and efficacy of isatuximab, pomalidomide, and dexamethasone as fourth-line therapy in patients with relapsed/refractory (R/R) multiple myeloma in the UK. The study reported a progression-free survival (PFS) and toxicity profile that was consistent with what had been observed in the ICARIA-MM study (NCT02990338). This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
